Stay updated with breaking news from Drug Controller General. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Drug Controller General of India (DCGI) has asked drug regulators in all states and Union territories to withdraw AstraZeneca's anti-cancer drug Olaparib tablets for treatment in patients who have received three or more prior lines of chemotherapy.
Wockhardt Limited reports reduced net loss, plans to launch new antibiotics, files patents, and raises funds for growth.
DCGI orders withdrawal of AstraZeneca's Olaparib tablets for gBRCA mutation and advanced ovarian cancer due to potential adverse effects. The drug was
The communication stated that the firm presented the clinical evidence for the withdrawal of indication of Olaparib tablets.
Oncologists on Thursday supported the Drug Controller General of India's (DCGI) mandate to state authorities to withdraw AstraZeneca's anticancer generic drug Olaparib over safety concerns.Olaparib is a chemotherapy drug and is used to treat ...